The next generation of peptide receptor radionuclide therapy.
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-[Tyr3]octreotate has been successfully developed in the last decades for the treatment of neuroendocrine neoplasms. However, different methods to improve the objective response rate and survival are under investigation. This includes changes of the radioligand, dosimetry and combination therapy with different agents, such as radiosensitizers. Hofving et al. recently reported in Endocrine-Related Cancer on the use of heat-shock protein 90 (Hsp90) modulation to augment radiation effects as a new promising target for radiosensitization. In this commentary, new developments in the field of PRRT are discussed, placing these new findings about Hsp90 inhibitors into context.